Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

R. Teerlink, John; Díaz, Rafael; Michael Felker, G.; J.V. McMurray, John; Metra, Marco; Solomon, Scott; F. Adams, Kirkwood; S. Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; G.F. Cleland, John; Corbalán, Ramón; G. Crespo‐Leiro, María; Dahlström, Ulf; Eduardo Echeverría, Luis; C. Fang, James; Filippatos, Gerasimos; Fonseca, Cândida; Gonçalvesová, Eva; Goudev, Assen; G. Howlett, Jonathan; E. Lanfear, David; Li, Jing; Lund, Mayanna; S. Macdonald, Peter; Mareev, Viacheslav; Momomura, Shin‐ichi; O’Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; José Alvarez Ramires, Félix; Šerpytis, Pranas; Sliwa, Karen; Špinar, Jindřich; Suter, Thomas; Tomcsányi, János; Vandekerckhove, Hans; Vinereanu, Dragoş; A. Voors, Adriaan; Birhan Yılmaz, Mehmet; Zannad, Faı̈ez; Sharpsten, Lucie; C. Legg, Jason; Varin, Claire; Honarpour, Narimon; Abbasi, Siddique; I. Malik, Fady; E. Kurtz, Christopher

doi:10.1056/nejmoa2025797

Public

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Published in New England Journal of Medicine • Nov 13, 2020

Authors:

John R. Teerlink

Rafael Díaz

G. Michael Felker

Abstract

BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigned 8256 patients (inpatients and outpatients)...

Subject

Cardiology

Medicine

Heart failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!